BioWorld

Sep. 24, 2004

View Archived Issues

Sopherion's Myocet Licensing Inspires $47M Series B Round

Sopherion Therapeutics Inc. raised $47 million in a Series B venture financing and, at the same time, entered a licensing deal with Zeneus Pharma Ltd. for Myocet, a breast cancer therapy approved in Europe and Canada. (BioWorld Today) Read More

Genaissance In-Licenses Merck's Depression Drug For Up To EUR36M

Read More

Old Approach Provides New Benefits In Dystrophy Model

Read More

Emisphere To Deliver rhGH For Novartis In Potential $34M Deal

Read More

Other News To Note

Read More

Appointments and Advancements

Read More